BIOTHERA FILES IND FOR IMPRIME PGG
Biothera has filed an investigational new drug application with the FDA for Imprime PGG for the treatment of cancer in combination with approved monoclonal antibodies, including Genentech's Herceptin.
Preclinical research indicated that Imprime PGG significantly enhanced the effectiveness of monoclonal antibody therapy to both kill tumors and increase long-term survival rates. Imprime PGG recruits and primes neutrophils, the most abundant type of immune cell in the body, to kill cancer cells targeted by monoclonal antibodies.
"The significance of this technology is that it engages a whole new arm of the immune system against cancer," said Ketan Desai, chief medical officer of Biothera.
Imprime PGG is an intravenous drug candidate derived from the cell walls of a proprietary form of Saccharomyces cerevisiae (Baker's yeast). There is a growing body of data supporting the ability of yeast beta glucans to benefit immune function and the body's efforts to protect itself from disease.